Open Biosystems Launches the Open Access RNAi Program
News Feb 03, 2006
Open Biosystems, Inc. has announced its Open Access RNAi Program. Participation in this program allows all research laboratories within an institution access to its choice of Open Biosystems' portfolio of genome-wide RNAi resources.
The Open Access RNAi Program is designed to support Open Biosystems' vision of supporting basic and medical research and reinforces its commitment to expanding access to research reagents for the life sciences community.
The Open Biosystems Open Access RNAi Program gives entire academic systems, including multiple campuses, access to the company's advanced shRNA libraries, priority technical support, continued access to all extensions of existing libraries as well as library upgrades.
In this manner, Open Biosystems will support university customers' research. The program is customizable and can be tailored to fit the diverse needs of research institutions worldwide.
"Open Biosystems has grown based on the strength of our technology, dedication to customer support and strong partnerships with the academic research community," said Troy Moore, Chief Technical Officer of Open Biosystems.
"We are providing access to leading-edge whole genome RNAi libraries, including the most versatile lentiviral RNAi research tool to date, in a supported, cost-effective manner."
"The Open Access RNAi Program addresses the key needs of our customers and continues our commitment to facilitate whole genome analysis at the bench top of individual scientists."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.